BWL
KYMR icon

Bogart Wealth LLC’s Kymera Therapeutics KYMR Stock Holding History

Bogart Wealth LLC’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5
Closed -$416 – 2056
2026
Q1 		$416 Buy
+5
New +$396 ﹤0.01% 1640

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Bogart Wealth LLC's KYMR Position: Q2 2026 in Review

Bogart Wealth LLC sold out of Kymera Therapeutics (KYMR) in Q2 2026, closing a stake of 5 shares — an estimated $416 sold.

Bogart Wealth LLC first reported a position in KYMR in Q1 2026 and held it in 1 quarter. The position peaked at $416 in Q1 2026. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Bogart Wealth LLC reported no remaining Kymera Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Bogart Wealth LLC sold 5 Kymera Therapeutics shares in Q2 2026, an estimated $416.
  • Bogart Wealth LLC first reported a position in Kymera Therapeutics in Q1 2026 and held it in 1 quarter.
  • Bogart Wealth LLC's Kymera Therapeutics position peaked at $416 in Q1 2026.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Bogart Wealth LLC's 13F filing for Q2 2026, filed 24 Jul 2026.